SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2019-07-04 (skipr.nl)
Dutch pharmaceutical company Synthon partly in British hands - Skipr
The Dutch pharmaceutical multinational Synthon has been sold in part to the British investment company BC Partners. It would be an amount between 500 million and 1 billion euros, sources report to De Telegraaf.
Read more
2019-03-19 (quotenet.nl)
Jacques Lemmens
Living in the NetherlandsOrigin of assets: FarmaWe know Jacques Lemmens (1952) as the founder of
Read more
2009-11-12 (europapress.es)
Economy/Business.- The pharmaceutical Synthon Hispania invests 8 million in its factory in Sant Boi (Barcelona)
The pharmaceutical company Synthon Hispania has invested eight million euros in a new line of...
Read more